Clinuvel Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Clinuvel Pharmaceuticals has been growing earnings at an average annual rate of 14.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 23.9% per year. Clinuvel Pharmaceuticals's return on equity is 16.9%, and it has net margins of 36.9%.
Key information
14.4%
Earnings growth rate
13.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 23.9% |
Return on equity | 16.9% |
Net Margin | 36.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Clinuvel Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 82 | 30 | 29 | 1 |
30 Sep 23 | 80 | 30 | 27 | 1 |
30 Jun 23 | 78 | 31 | 25 | 1 |
31 Mar 23 | 74 | 29 | 23 | 1 |
31 Dec 22 | 70 | 26 | 21 | 1 |
30 Sep 22 | 68 | 24 | 20 | 1 |
30 Jun 22 | 66 | 21 | 19 | 1 |
31 Mar 22 | 62 | 22 | 18 | 1 |
31 Dec 21 | 57 | 24 | 17 | 1 |
30 Sep 21 | 53 | 24 | 16 | 1 |
30 Jun 21 | 48 | 25 | 14 | 1 |
31 Mar 21 | 43 | 23 | 14 | -1 |
31 Dec 20 | 38 | 21 | 14 | -3 |
30 Sep 20 | 35 | 18 | 13 | -1 |
30 Jun 20 | 33 | 15 | 12 | 0 |
31 Mar 20 | 32 | 15 | 10 | 4 |
31 Dec 19 | 32 | 15 | 8 | 8 |
30 Sep 19 | 32 | 16 | 7 | 7 |
30 Jun 19 | 31 | 18 | 6 | 7 |
31 Mar 19 | 29 | 17 | 6 | 7 |
31 Dec 18 | 27 | 16 | 6 | 6 |
30 Sep 18 | 26 | 15 | 6 | 6 |
30 Jun 18 | 25 | 13 | 6 | 6 |
31 Mar 18 | 21 | 10 | 6 | 5 |
31 Dec 17 | 17 | 6 | 6 | 5 |
30 Sep 17 | 17 | 7 | 6 | 4 |
30 Jun 17 | 17 | 7 | 5 | 4 |
31 Mar 17 | 14 | 5 | 5 | 4 |
31 Dec 16 | 12 | 3 | 4 | 4 |
30 Sep 16 | 9 | 0 | 4 | 4 |
30 Jun 16 | 7 | -3 | 5 | 4 |
31 Mar 16 | 5 | -5 | 3 | 3 |
31 Dec 15 | 4 | -6 | 2 | 3 |
30 Sep 15 | 4 | -8 | 4 | 3 |
30 Jun 15 | 3 | -10 | 6 | 3 |
31 Mar 15 | 3 | -10 | 8 | 3 |
31 Dec 14 | 3 | -10 | 9 | 3 |
30 Sep 14 | 3 | -8 | 7 | 3 |
30 Jun 14 | 3 | -6 | 5 | 3 |
31 Mar 14 | 3 | -6 | 5 | 3 |
31 Dec 13 | 2 | -6 | 5 | 3 |
30 Sep 13 | 2 | -6 | 5 | 4 |
30 Jun 13 | 2 | -7 | 5 | 4 |
Quality Earnings: CLVL.Y has high quality earnings.
Growing Profit Margin: CLVL.Y's current net profit margins (36.9%) are lower than last year (37.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLVL.Y's earnings have grown by 14.4% per year over the past 5 years.
Accelerating Growth: CLVL.Y's earnings growth over the past year (14.2%) is below its 5-year average (14.4% per year).
Earnings vs Industry: CLVL.Y earnings growth over the past year (14.2%) exceeded the Biotechs industry -14%.
Return on Equity
High ROE: CLVL.Y's Return on Equity (16.9%) is considered low.